This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/05/2026
Select patients for treatment with RYBREVANT FASPRO as shown in Table: Patient Selection.
| Indication | Treatment Regimen | Source for Testinga |
|---|---|---|
| NSCLC | ||
| First-line treatment of NSCLC with EGFR Exon19del or Exon 21 L858R substitution mutations | RYBREVANT FASPRO in combination with LAZCLUZE |
|
| Previously treated locally advanced or metastatic NSCLC with EGFR Exon19del or Exon 21 L858R substitution mutations (progressive disease on an EGFR tyrosine kinase inhibitor) | RYBREVANT FASPRO in combination with carboplatin and pemetrexed | |
| First-line treatment of NSCLC with EGFR Exon20ins mutations | RYBREVANT FASPRO in combination with carboplatin and pemetrexed | |
| Previously treated NSCLC with EGFR Exon20ins mutations | RYBREVANT FASPRO as a single agent | |
| HNSCC | ||
| Previously treated HNSCC | RYBREVANT FASPRO as a single agent |
|
| Abbreviations: EGFR, epidermal growth factor receptor; Exon19del, Exon 19 deletion; Exon20ins, Exon 20 insertion; FDA, Food and Drug Administration; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; OPSCC, oropharyngeal squamous cell carcinoma. aInformation on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics. | ||
RYBREVANT FASPRO has different recommended dosages and dosing schedules based upon the indication. Calculate the dosage using baseline body weight. Administer until disease progression or unacceptable toxicity. See Table: Recommended Dosages and Dosing Schedules.
| Indication | Recommended Dosages and Dosing Schedules |
|---|---|
| NSCLC, as a single agent or in combination with LAZCLUZE | Q2W dosing or Q4W dosing |
| NSCLC, in combination with carboplatin and pemetrexed | Q3W dosing |
| HNSCC, as a single agent | Q4W dosing or Q3W dosing |
| Abbreviations: HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W, every 4 weeks. | |
The recommended dosages of RYBREVANT FASPRO for Q2W dosing are provided in the table below.
| Indication | Body Weight at Baselinea | Recommended Dose | Dosing Schedule |
|---|---|---|---|
NSCLC:
| <80 kg | 1600 mg amivantamab and 20,000 units hyaluronidase | Weekly (total of 4 doses) from Weeks 1 to 4
|
| Q2W starting at Week 5 onwardsb | |||
| ≥80 kg | 2240 mg amivantamab and 28,000 units hyaluronidase | Weekly (total of 4 doses) from Weeks 1 to 4
| |
| Q2W starting at Week 5 onwardsb | |||
| Abbreviations: NSCLC, non-small cell lung cancer; Q2W, every 2 weeks; Q4W, every 4 weeks. aDose adjustments not required for subsequent body weight changes.bMay switch to RYBREVANT FASPRO Q4W dosing regimen at their next scheduled dose on or after Week 5. (See Table: Recommended Dosage for RYBREVANT FASPRO (Q4W Dosing). | |||
The recommended dosages of RYBREVANT FASPRO for Q4W dosing are provided in the table below.3
| Indication | Body Weight at Baselinea | Recommended Dose | Dosing Schedule |
|---|---|---|---|
NSCLC:
| <80 kg | 1600 mg amivantamab and 20,000 units hyaluronidase | Weekly (total of 4 doses) from Weeks 1 to 4
|
| 3520 mg amivantamab and 44,000 units hyaluronidase | Q4W starting at Week 5 onwards | ||
| ≥80 kg | 2240 mg amivantamab and 28,000 units hyaluronidase | Weekly (total of 4 doses) from Weeks 1 to 4
| |
| 4640 mg amivantamab and 58,000 units hyaluronidase | Q4W starting at Week 5 onwards | ||
| Abbreviations: HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; Q4W, every 4 weeks. aDose adjustments not required for subsequent body weight changes. | |||
Order of Administration
When given in combination with LAZCLUZE for NSCLC, administer RYBREVANT FASPRO any time after LAZCLUZE when given on the same day. Refer to the LAZCLUZE Prescribing Information for recommended LAZCLUZE dosing information. Administer RYBREVANT FASPRO in combination with LAZCLUZE until disease progression or unacceptable toxicity.3
RYBREVANT FASPRO - Q3W Dosing
The recommended dosages of RYBREVANT FASPRO for Q3W dosing are provided in the table below.3
| Indication | Body Weight at Baselinea | Recommended Dose | Dosing Schedule |
|---|---|---|---|
NSCLC:
HNSCC:
| <80 kg | 1600 mg amivantamab and 20,000 units hyaluronidase | First dose at Week 1 Day 1 |
| 2400 mg amivantamab and 30,000 units hyaluronidase | Weekly (total of 2 doses) from Weeks 2 to 3
| ||
| Q3W starting at Week 4 onwards | |||
| ≥80 kg | 2240 mg amivantamab and 28,000 units hyaluronidase | First dose at Week 1 Day 1 | |
| 3360 mg amivantamab and 42,000 units hyaluronidase | Weekly (total of 2 doses) from Weeks 2 to 3
| ||
| Q3W starting at Week 4 onwards | |||
| Abbreviations: HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; Q3W, every 3 weeks. aDose adjustments not required for subsequent body weight changes. | |||
Order of Administration
The recommended order of administration and regimen for RYBREVANT FASPRO in combination with carboplatin and pemetrexed for NSCLC are provided in the table below.3
| Administer the regimen in the following order: pemetrexed first, carboplatin second, and RYBREVANT FASPRO last. | ||
|---|---|---|
| Drug | Dose | Duration/Timing of Treatment |
| Pemetrexed | Pemetrexed 500 mg/m2 IV. Refer to the pemetrexed Full PI for complete information. |
|
| Carboplatin | Carboplatin AUC 5 IV. Refer to the carboplatin Full PI for complete information. |
|
| RYBREVANT FASPRO | RYBREVANT FASPRO SC. See Table: Recommended Dosage for RYBREVANT FASPRO (Q3W Dosing). |
|
| Abbreviations: AUC, area under curve; IV, intravenously; NSCLC, non-small cell lung cancer; PI, Prescribing Information; Q3W, every 3 weeks; SC, subcutaneously. | ||
Prior to the initial injection of RYBREVANT FASPRO (Week 1 Day 1), administer premedications as described in the table below to reduce the risk of ARRs.3
Glucocorticoid administration is required at the initial dose at Week 1 Day 1 only, and upon re‑initiation after prolonged dose interruptions, then as necessary for subsequent injections (see table below). Administer both antihistamine and antipyretic prior to all RYBREVANT FASPRO doses.3
| Medication | Dose | Route of Administration | Dosing Window Prior to RYBREVANT FASPRO Administration |
|---|---|---|---|
| Antihistaminea | Diphenhydramine (25-50 mg) or equivalent | IV | 15-30 minutes |
| Oral | 30-60 minutes | ||
| Antipyretica | Acetaminophen (650-1000 mg) or equivalent | IV | 15-30 minutes |
| Oral | 30-60 minutes | ||
| Glucocorticoidb | Dexamethasone (20 mg) or equivalent | IV | 45-60 minutes |
| Oral | At least 60 minutes | ||
| Glucocorticoidc | Dexamethasone (10 mg) or equivalent | IV | 45-60 minutes |
| Oral | 60-90 minutes | ||
| Abbreviations: ARR, administration-related reaction; IV, intravenous. aRequired at all doses. bRequired at initial dose (Week 1 Day 1) or at the next subsequent dose in the event of an ARR. cOptional for subsequent doses. | |||
When initiating treatment with RYBREVANT FASPRO, prophylactic and concomitant medications are recommended to reduce the risk and severity of dermatologic ARs.3
When initiating treatment with RYBREVANT FASPRO in combination with LAZCLUZE, administer anticoagulant prophylaxis to prevent venous thromboembolic (VTE) events for the first 4 months of treatment. If there are no signs or symptoms of VTE events during the first 4 months of treatment, consider discontinuation of anticoagulant prophylaxis at the discretion of the healthcare provider. Refer to the LAZCLUZE Prescribing Information for information about concomitant medications.3
If the missed dose is not administered according to this guidance, do not administer the missed dose and administer the next dose per the usual dosing schedule.3
The recommended RYBREVANT FASPRO dose reductions for ARs are listed in the table below.3
| Dosea | 1st Dose Reduction | 2nd Dose Reduction | 3rd Dose Reduction |
|---|---|---|---|
| 1600 mg amivantamab and 20,000 units hyaluronidase | 1050 mg amivantamab and 13,200 units hyaluronidaseb | 700 mg amivantamab and 8800 units hyaluronidasec | Discontinue RYBREVANT FASPRO |
| 2240 mg amivantamab and 28,000 units hyaluronidase | 1600 mg amivantamab and 20,000 units hyaluronidased | 1050 mg amivantamab and 13,200 units hyaluronidaseb | |
| 2400 mg amivantamab and 30,000 units hyaluronidase | 1600 mg amivantamab and 20,000 units hyaluronidased | 1050 mg amivantamab and 13,200 units hyaluronidaseb | |
| 3360 mg amivantamab and 42,000 units hyaluronidase | 2240 mg amivantamab and 28,000 units hyaluronidasee | 1600 mg amivantamab and 20,000 units hyaluronidased | |
| 3520 mg amivantamab and 44,000 units hyaluronidase | 2400 mg amivantamab and 30,000 units hyaluronidasef | 1600 mg amivantamab and 20,000 units hyaluronidased | |
| 4640 mg amivantamab and 58,000 units hyaluronidase | 3360 mg amivantamab and 42,000 units hyaluronidaseg | 2240 mg amivantamab and 28,000 units hyaluronidasee | |
| Abbreviation: AR, adverse reaction. aDose at which the AR occurred. bThe dose volume should be 6.6 mL for 1050 mg amivantamab and 13,200 units hyaluronidase dose. cThe dose volume should be 4.4 mL for 700 mg amivantamab and 8800 units hyaluronidase dose. dThe dose volume should be 10 mL for 1600 mg amivantamab and 20,000 units hyaluronidase dose. eThe dose volume should be 14 mL for 2240 mg amivantamab and 28,000 units hyaluronidase dose.fThe dose volume should be 15 mL for 2400 mg amivantamab and 30,000 units hyaluronidase dose.gThe dose volume should be 21 mL for 3360 mg amivantamab and 42,000 units hyaluronidase dose. | |||
The recommended RYBREVANT FASPRO dosage modifications and management for ARs are provided in the table below.3
| AR | Severity | Dosage Modifications |
|---|---|---|
| Hypersensitivity and ARRs | Grade 1 or 2 |
|
| Grade 3 |
| |
| Grade 4 | Permanently discontinue RYBREVANT FASPRO. | |
| ILD/pneumonitis | Any grade |
|
| VTE events (applies to when used in combination with LAZCLUZE) | Grade 2 or 3 |
|
| ||
| Dermatologic ARs (including dermatitis acneiform, pruritus, dry skin) | Grade 1 or 2 |
|
| Grade 3 |
| |
| Grade 4 or Severe bullous, blistering or exfoliating skin conditions (including TEN) | Permanently discontinue RYBREVANT FASPRO. | |
| Other ARs | Grade 3 |
|
| Grade 4 |
| |
| Abbreviations: AR, adverse reaction; ARR, administration-related reaction; ILD, interstitial lung disease; TEN, toxic epidermal necrolysis; VTE, venous thromboembolic. | ||
When administering RYBREVANT FASPRO in combination with LAZCLUZE, if there is an AR requiring dose reduction after withholding treatment and resolution, reduce the dose of RYBREVANT FASPRO first. Refer to the LAZCLUZE Prescribing Information for information about dosage modifications for LAZCLUZE.3
When administering RYBREVANT FASPRO in combination with carboplatin and pemetrexed, modify the dosage of 1 or more drugs. Withhold or discontinue RYBREVANT FASPRO as shown in Table: Recommended RYBREVANT FASPRO Dosage Modifications and Management for ARs. Refer to Prescribing Information for carboplatin and pemetrexed for additional dosage modification information.3
| RYBREVANT FASPRO Total Dose | Total Dose Volume |
|---|---|
| 1600 mg amivantamab and 20,000 units hyaluronidase | 10 mL |
| 2240 mg amivantamab and 28,000 units hyaluronidase | 14 mL |
| 2400 mg amivantamab and 30,000 units hyaluronidase | 15 mL |
| 3360 mg amivantamab and 42,000 units hyaluronidase | 21 mLa,b |
| 3520 mg amivantamab and 44,000 units hyaluronidase | 22 mLb |
| 4640 mg amivantamab and 58,000 units hyaluronidase | 29 mLb,c |
| aFor the 21 mL dose volume, the entire contents of the 3520 mg amivantamab and 44,000 units hyaluronidase/22 mL vial will not be needed. Discard unused portion.bDivide the dose volume approximately equally into 2 syringes (each syringe should not exceed 15 mL).cFor the 29 mL dose volume, use one 2240 mg amivantamab and 28,000 units hyaluronidase/14 mL vial and one 2400 mg amivantamab and 30,000 units hyaluronidase/15 mL vial to minimize waste. If a different combination of vials is used, discard unused portion. | |
RYBREVANT FASPRO is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.
A literature search of MEDLINE®
| 1 | Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593-3605. |
| 2 | |
| 3 |
Would you like to clear and leave your conversation? Message history will be lost.